文献速递临床试验与 GCP流行病学与生物统计

冠脉血运重建后P2Y12抑制剂单药与双联抗血小板治疗的个体患者水平荟萃分析

P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials.
PubMed 文献 · BMJ · 2021-06-16

结果显示单药组主要复合终点(全因死亡、心肌梗死、卒中)风险与DAPT相似(HR 0.93,95%CI 0.79-1.09,非劣效P=0.005),出血风险显著降低(HR 0.49,95%CI 0.39-0.63,P<0.001),疗效受性别和治疗方案中P2Y12抑制剂类型影响。

要点

  • P2Y12抑制剂单药在主要缺血终点上非劣于DAPT,且大出血风险降低约一半。
  • 女性可能从单药治疗中更多获益(HR 0.64),男性未见获益(HR 1.00)。
  • DAPT方案中含新型P2Y12抑制剂者,单药治疗的出血获益更明显。

核心结论

  • P2Y12抑制剂单药与DAPT在全因死亡、心肌梗死或卒中风险上相似,且出血风险更低。

研究设计与样本

  • 检索Ovid Medline、Embase及三个网站至2020年7月16日,由主要作者提供个体数据。

主要发现

  • 符合方案人群主要终点:单药组283例(2.95%),DAPT组315例(3.27%),HR 0.93(95%CI 0.79-1.09),非劣效P=0.005,优效性P=0.38。
  • 意向治疗人群主要终点:单药组303例(2.94%),DAPT组338例(3.36%),HR 0.90(95%CI 0.77-1.05),优效性P=0.18。
  • BARC 3或5型出血:单药组97例(0.89%),DAPT组197例(1.83%),HR 0.49(95%CI 0.39-0.63),P<0.001。
  • 性别交互作用P=0.02:女性主要缺血终点HR 0.64(95%CI 0.46-0.89),男性HR 1.00(95%CI 0.83-1.19)。
  • P2Y12抑制剂类型交互作用P=0.02:DAPT中含新型P2Y12抑制剂时单药出血获益更明显。

临床怎么用

  • 对于无口服抗凝指征的冠脉血运重建后患者,可考虑P2Y12抑制剂单药替代DAPT以降低出血风险。
  • 女性患者可能从单药治疗中获得额外缺血获益,决策时可结合性别因素个体化。
  • 若DAPT方案中含新型P2Y12抑制剂,转换为单药治疗的出血获益可能更显著。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the risks and benefits of P2Y12 inhibitor monotherapy compared with dual antiplatelet therapy (DAPT) and whether these associations are modified by patients' characteristics. DESIGN: Individual patient level meta-analysis of randomised controlled trials. DATA SOURCES: Searches were conducted in Ovid Medline, Embase, and three websites (www.tctmd.com, www.escardio.org, www.acc.org/cardiosourceplus) from inception to 16 July 2020. The primary authors provided individual participant data. ELIGIBILITY CRITERIA: Randomised controlled trials comparing effects of oral P2Y12 monotherapy and DAPT on centrally adjudicated endpoints after coronary revascularisation in patients without an indication for oral anticoagulation. MAIN OUTCOME MEASURES: The primary outcome was a composite of all cause death, myocardial infarction, and stroke, tested for non-inferiority against a margin of 1.15 for the hazard ratio. The key safety endpoint was Bleeding Academic Research Consortium (BARC) type 3 or type 5 bleeding. RESULTS: The meta-analysis included data from six trials, including 24 096 patients. The primary outcome occurred in 283 (2.95%) patients with P2Y12 inhibitor monotherapy and 315 (3.27%) with DAPT in the per protocol population (hazard ratio 0.93, 95% confidence interval 0.79 to 1.09; P=0.005 for non-inferiority; P=0.38 for superiority; τ2=0.00) and in 303 (2.94%) with P2Y12 inhibitor monotherapy and 338 (3.36%) with DAPT in the intention to treat population (0.90, 0.77 to 1.05; P=0.18 for superiority; τ2=0.00). The treatment effect was consistent across all subgroups, except for sex (P for interaction=0.02), suggesting that P2Y12 inhibitor monotherapy lowers the risk of the primary ischaemic endpoint in women (hazard ratio 0.64, 0.46 to 0.89) but not in men (1.00, 0.83 to 1.19). The risk of bleeding was lower with P2Y12 inhibitor monotherapy than with DAPT (97 (0.89%) v 197 (1.83%); hazard ratio 0.49, 0.39 to 0.63; P<0.001; τ2=0.03), which was consistent across subgroups, except for type of P2Y12 inhibitor (P for interaction=0.02), suggesting greater benefit when a newer P2Y12 inhibitor rather than clopidogrel was part of the DAPT regimen. CONCLUSIONS: P2Y12 inhibitor monotherapy was associated with a similar risk of death, myocardial infarction, or stroke, with evidence that this association may be modified by sex, and a lower bleeding risk compared with DAPT. REGISTRATION: PROSPERO CRD42020176853.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Valgimigli M, Gragnano F, Branca M, et al. P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials. BMJ. 2021. PMID: 34135011. doi:10.1136/bmj.n1332

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。